Department of Public Health Programmes, Randers Regional Hospital, Skovlyvej 15, 8930, Randers, NØ, Denmark.
Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 82, 8200, Aarhus N, Denmark.
BMC Cancer. 2018 Mar 9;18(1):273. doi: 10.1186/s12885-018-4165-4.
Cervical cancer screening participation remains insufficient in most countries. Our aim was to evaluate whether offering a HPV self-sampling kit, either mailed directly to the woman's home or using timely opt-in procedures for ordering the kit, increased screening participation compared with a standard second reminder.
In this randomized, controlled effectiveness trial, 9791 Danish women aged 30-64 who were due to receive the second reminder were equally randomized to either: 1) direct mailing of a second reminder and a self-sampling kit (directly mailed group); 2) mailing of a second reminder that offered a self-sampling kit to be ordered by e-mail, text message, phone, or webpage (opt-in group); or 3) mailing of a second reminder to attend regular cytology screening (control group). In an intention-to-treat analysis, we estimated the participation rate at 180 days post intervention, by returning a self-sample or attending regular cytology screening. We calculated the proportion of women with a positive HPV self-sample who attended for cervical cytology triage at the general practitioner within 90 days.
Participation was significantly higher in the directly mailed group (38.0%) and in the opt-in group (30.9%) than in the control group (25.2%) (participation difference (PD): 12.8%, 95% CI: 10.6-15.0% and PD: 5.7%, 95% CI: 3.5-7.9%, respectively). Within 90 days, 107 women (90.7%, 95% CI: 83.9-95.3%) with a HPV-positive self-sample attended follow-up.
Offering the opportunity of HPV self-sampling as an alternative to regular cytology screening increased participation; the direct mailing strategy was the most effective invitation strategy. A high compliance with follow-up was seen.
Current Controlled Trials NCT02680262 . Registered 10 February 2016.
在大多数国家,宫颈癌筛查的参与率仍然不足。我们的目的是评估直接将 HPV 自我采样套件邮寄给妇女的家,或通过及时的选择加入程序订购套件,与标准的第二次提醒相比,是否会增加筛查参与率。
在这项随机、对照有效性试验中,9791 名年龄在 30-64 岁之间的丹麦妇女即将收到第二次提醒,她们被平均随机分为三组:1)直接邮寄第二次提醒和自我采样套件(直接邮寄组);2)邮寄第二次提醒,提供通过电子邮件、短信、电话或网页订购自我采样套件的选项(选择加入组);或 3)邮寄第二次提醒参加常规细胞学筛查(对照组)。在意向治疗分析中,我们通过返回自我样本或参加常规细胞学筛查来估计干预后 180 天的参与率。我们计算了 HPV 自我样本阳性的妇女中,在 90 天内到全科医生进行宫颈细胞学分类的比例。
直接邮寄组(38.0%)和选择加入组(30.9%)的参与率明显高于对照组(25.2%)(参与率差异(PD):12.8%,95%CI:10.6-15.0%和 PD:5.7%,95%CI:3.5-7.9%)。在 90 天内,107 名 HPV 阳性自我样本的妇女(90.7%,95%CI:83.9-95.3%)接受了随访。
提供 HPV 自我采样作为常规细胞学筛查的替代方案增加了参与率;直接邮寄策略是最有效的邀请策略。我们看到了很高的随访依从性。
当前对照试验 NCT02680262。于 2016 年 2 月 10 日注册。